公开(公告)号：US5643562A

公开(公告)日：1997-07-01

申请号：US403230

申请日：1995-03-15

申请人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

发明人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

IPC分类号： A61K31/185 ,  A61K31/255 ,  A61K31/41 ,  A61K31/70 ,  A61K31/737 ,  A61K31/795 ,  A61K47/48 ,  A61L33/08 ,  C07H11/00 ,  C07H15/04 ,  A61K31/74 ,  A61K31/785 ,  A61K47/32

CPC分类号： C07H15/04 ,  A61K31/185 ,  A61K31/255 ,  A61K31/41 ,  A61K31/70 ,  A61K31/737 ,  A61K31/795 ,  A61K47/48007 ,  A61K47/48023 ,  A61K47/48092 ,  A61K47/481 ,  A61K47/4813 ,  A61K47/48176 ,  A61L33/08 ,  C07H11/00

摘要： Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

摘要翻译： 描述了用于抑制受试者中淀粉样蛋白沉积的治疗化合物和方法，无论其临床情况如何。 通过给予受试者有效量的包含阴离子基团和载体分子或其药学上可接受的盐的治疗化合物或其淀粉样蛋白形成蛋白质与基底膜成分之间的相互作用被抑制来抑制淀粉样蛋白沉积。 优选的阴离子基团是磺酸盐和硫酸盐。 优选的载体分子包括碳水化合物，聚合物，肽，肽衍生物，脂族基团，脂环族基团，杂环基团，芳族基团及其组合。

公开(公告)号：US20060167095A1

公开(公告)日：2006-07-27

申请号：US11316378

申请日：2005-12-22

申请人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

发明人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

IPC分类号： A61K31/185

CPC分类号： C07H15/04 ,  A61K31/095 ,  A61K31/185 ,  A61K31/255 ,  A61K31/34 ,  A61K31/41 ,  A61K31/70 ,  A61K47/51 ,  A61K47/549 ,  A61K47/55 ,  A61K47/555 ,  A61K47/58 ,  C07C305/10 ,  C07C309/05 ,  C07D491/04 ,  C07H11/00

摘要： Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

公开(公告)号：US5840294A

公开(公告)日：1998-11-24

申请号：US542997

申请日：1995-10-13

申请人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

发明人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

IPC分类号： C07D409/04 ,  A61K31/185 ,  A61K31/255 ,  A61K31/41 ,  A61K31/70 ,  A61K31/7024 ,  A61K31/737 ,  A61K31/795 ,  A61K45/00 ,  A61K47/48 ,  A61L33/08 ,  A61P3/10 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P43/00 ,  C07D257/04 ,  C07H11/00 ,  C07H15/04 ,  A61K31/74 ,  A61F2/02 ,  A61K31/785

CPC分类号： A61K31/185 ,  A61K31/255 ,  A61K31/41 ,  A61K31/70 ,  A61K31/737 ,  A61K31/795 ,  A61K47/48007 ,  A61K47/48023 ,  A61K47/48092 ,  A61K47/481 ,  A61K47/4813 ,  A61K47/48176 ,  A61L33/08 ,  C07H11/00 ,  C07H15/04

摘要： Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

公开(公告)号：US5728375A

公开(公告)日：1998-03-17

申请号：US472692

申请日：1995-06-06

申请人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

发明人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

IPC分类号： A61K31/185 ,  A61K31/255 ,  A61K31/41 ,  A61K31/70 ,  A61K31/737 ,  A61K31/795 ,  A61K47/48 ,  A61L33/08 ,  C07H11/00 ,  C07H15/04 ,  A61K31/74 ,  A61K31/785 ,  A61K47/32

CPC分类号： C07H15/04 ,  A61K31/185 ,  A61K31/255 ,  A61K31/41 ,  A61K31/70 ,  A61K31/737 ,  A61K31/795 ,  A61K47/48007 ,  A61K47/48023 ,  A61K47/48092 ,  A61K47/481 ,  A61K47/4813 ,  A61K47/48176 ,  A61L33/08 ,  C07H11/00

摘要： Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

公开(公告)号：US20070265334A1

公开(公告)日：2007-11-15

申请号：US11707758

申请日：2007-02-16

申请人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

发明人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

IPC分类号： A61K31/095 ,  A61K31/34 ,  A61P3/00 ,  C07C317/04 ,  C07D307/00

CPC分类号： C07H15/04 ,  A61K31/095 ,  A61K31/185 ,  A61K31/255 ,  A61K31/34 ,  A61K31/41 ,  A61K31/70 ,  A61K47/51 ,  A61K47/549 ,  A61K47/55 ,  A61K47/555 ,  A61K47/58 ,  C07C305/10 ,  C07C309/05 ,  C07D491/04 ,  C07H11/00

摘要： Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

摘要翻译： 描述了用于抑制受试者中淀粉样蛋白沉积的治疗化合物和方法，无论其临床情况如何。 通过给予受试者有效量的包含阴离子基团和载体分子或其药学上可接受的盐的治疗化合物或其淀粉样蛋白形成蛋白质与基底膜成分之间的相互作用被抑制来抑制淀粉样蛋白沉积。 优选的阴离子基团是磺酸盐和硫酸盐。 优选的载体分子包括碳水化合物，聚合物，肽，肽衍生物，脂族基团，脂环族基团，杂环基团，芳族基团及其组合。

公开(公告)号：US20070004680A1

公开(公告)日：2007-01-04

申请号：US11096239

申请日：2005-03-30

申请人： Kazimierz Babinski ,  Walter Szarek ,  Rahul Vohra ,  Thomas Varming ,  Philip Ahring ,  Tino Joergensen ,  Gordon Blackburn-Munro

发明人： Kazimierz Babinski ,  Walter Szarek ,  Rahul Vohra ,  Thomas Varming ,  Philip Ahring ,  Tino Joergensen ,  Gordon Blackburn-Munro

IPC分类号： A61K31/675 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4709

CPC分类号： A61K31/4709 ,  A61K31/49 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/675

摘要： The present invention relates to compositions and methods to modulate the activity of gated ion channels.

摘要翻译： 本发明涉及调节离子通道活性的组合物和方法。

公开(公告)号：US5972328A

公开(公告)日：1999-10-26

申请号：US463548

申请日：1995-06-05

申请人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

发明人： Robert Kisilevsky ,  Walter Szarek ,  Donald Weaver

IPC分类号： A61K31/185 ,  A61K31/255 ,  A61K31/41 ,  A61K31/70 ,  A61K31/737 ,  A61K31/795 ,  A61K47/48 ,  A61L33/08 ,  C07H11/00 ,  C07H15/04 ,  A61K31/74 ,  A61K31/785 ,  A61K47/32

CPC分类号： A61K31/185 ,  A61K31/255 ,  A61K31/41 ,  A61K31/70 ,  A61K31/737 ,  A61K31/795 ,  A61K47/48007 ,  A61K47/48023 ,  A61K47/48092 ,  A61K47/481 ,  A61K47/4813 ,  A61K47/48176 ,  A61L33/08 ,  C07H11/00 ,  C07H15/04

摘要： Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.